Landos Biopharma, Inc.
Total raised
$60 M
1 round on record
Latest round
$60 M
Aug 2019
First round on record
Aug 2019
Today
Private
No later event on record
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2019 | $60 M | No. 1 | $50 to $250 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Landos Biopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2019).
SEC Form D · Aug 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2019
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
2 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Nomura Healthcare Fund | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, Jun 2026) | SEC Form N-PORT |
| The Gabelli ABC Fund | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, Jun 2026) | SEC Form N-PORT |
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Josep Bassaganya-Riera | Executive officer | Aug 2019 |
| Christopher Garabedian | Director | Aug 2019 |
| Josep Bassaganya-Riera | Director | Aug 2019 |